The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer
Abstract Background Immune checkpoint pathways play important roles in breast cancer (BC) pathogenesis and therapy. Methods Expression levels of programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), programmed death-ligand 1 (PD-L1), Forkhead box P3 (FOXP3), m...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10020-025-01137-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849390347295129600 |
|---|---|
| author | Eman A. Al-Sharabass Motawa E. EL-Houseini Heba Effat Sherif Abdelaziz Ibrahim Mona S. Abdellateif |
| author_facet | Eman A. Al-Sharabass Motawa E. EL-Houseini Heba Effat Sherif Abdelaziz Ibrahim Mona S. Abdellateif |
| author_sort | Eman A. Al-Sharabass |
| collection | DOAJ |
| description | Abstract Background Immune checkpoint pathways play important roles in breast cancer (BC) pathogenesis and therapy. Methods Expression levels of programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), programmed death-ligand 1 (PD-L1), Forkhead box P3 (FOXP3), miR-155, and miR-195 were assessed in the peripheral blood of 90 BC patients compared to 30 healthy controls using quantitative real-time PCR (qRt-PCR). The plasma level of soluble MHC class I chain related-protein B (MIC-B) protein was assessed using the enzyme linked immunosorbent assay (ELISA) technique. The data were correlated to the clinico-pathological characteristics of the patients. Results There was a significant increase in the expression levels of PDL-1 [17.59 (3.24–123), p < 0.001], CTLA-4 [23.34 (1.3–1267), p = 0.006], PD-1 [10.25 (1–280), p < 0.001], FOXP3 [11.5 (1–234.8), p = 0.001], miR-155 [87.3 (1.5–910), p < 0.001] in BC patients compared to normal controls. The miR-195 was significantly downregulated in BC patients [0.23 (0–0.98, p < 0.001]. The plasma level of MIC-B was significantly increased in the BC patients [0.941 (0.204–6.38) ng/ml], compared to the control group [0.351 (0.211–0.884) ng/mL, p < 0.00]. PDL-1, CTLA-4, PD-1, and FOXP3 achieved a specificity of 100% for distinguishing BC patients, at a sensitivity of 93.3%, 82.2%, 62.2%, and 71.1% respectively. The combined expression of PDL-1 and CTLA-4 scored a 100% sensitivity and 100% specificity for diagnosing BC (p < 0.001). The sensitivity, specificity, and AUC of miR-155 were 88.9%, 96.7%, and 0.934; respectively (p < 0.001). While those of miR-195 were 73.3%, 60%, and 0.716; respectively (p = 0.001). MIC-B expression showed a 77.8% sensitivity, 80% specificity, and 0.811 AUC at a cutoff of 1.17 ng/ml (p < 0.001). Combined expression of miR-155 and miR-195 achieved a sensitivity of 91.1%, a specificity of 96.7%, and AUC of 0.926 (p < 0.001). Multivariate analysis showed that PDL-1 (OR:13.825, p = 0.004), CTLA-4 (OR: 20.958, p = 0.010), PD-1(OR:10.550, p = 0.044), MIC-B (OR: 17.89, p = 0.003), miR-155 (OR: 211.356, P < 0.001), and miR-195(OR:0.006, P < 0.001) were considered as independent risk factors for BC. Conclusions The PB levels of PDL-1, CTLA-4, PD-1, FOXP3, MIC-B, miR-155, and miR-195 could be used as promising diagnostic markers for BC patients. |
| format | Article |
| id | doaj-art-fe3f1a3f00e04574a961a1fce111bfd8 |
| institution | Kabale University |
| issn | 1528-3658 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Medicine |
| spelling | doaj-art-fe3f1a3f00e04574a961a1fce111bfd82025-08-20T03:41:42ZengBMCMolecular Medicine1528-36582025-03-0131111410.1186/s10020-025-01137-1The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancerEman A. Al-Sharabass0Motawa E. EL-Houseini1Heba Effat2Sherif Abdelaziz Ibrahim3Mona S. Abdellateif4Zoology Department, Faculty of Science, Cairo UniversityMedical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo UniversityMedical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo UniversityZoology Department, Faculty of Science, Cairo UniversityMedical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo UniversityAbstract Background Immune checkpoint pathways play important roles in breast cancer (BC) pathogenesis and therapy. Methods Expression levels of programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), programmed death-ligand 1 (PD-L1), Forkhead box P3 (FOXP3), miR-155, and miR-195 were assessed in the peripheral blood of 90 BC patients compared to 30 healthy controls using quantitative real-time PCR (qRt-PCR). The plasma level of soluble MHC class I chain related-protein B (MIC-B) protein was assessed using the enzyme linked immunosorbent assay (ELISA) technique. The data were correlated to the clinico-pathological characteristics of the patients. Results There was a significant increase in the expression levels of PDL-1 [17.59 (3.24–123), p < 0.001], CTLA-4 [23.34 (1.3–1267), p = 0.006], PD-1 [10.25 (1–280), p < 0.001], FOXP3 [11.5 (1–234.8), p = 0.001], miR-155 [87.3 (1.5–910), p < 0.001] in BC patients compared to normal controls. The miR-195 was significantly downregulated in BC patients [0.23 (0–0.98, p < 0.001]. The plasma level of MIC-B was significantly increased in the BC patients [0.941 (0.204–6.38) ng/ml], compared to the control group [0.351 (0.211–0.884) ng/mL, p < 0.00]. PDL-1, CTLA-4, PD-1, and FOXP3 achieved a specificity of 100% for distinguishing BC patients, at a sensitivity of 93.3%, 82.2%, 62.2%, and 71.1% respectively. The combined expression of PDL-1 and CTLA-4 scored a 100% sensitivity and 100% specificity for diagnosing BC (p < 0.001). The sensitivity, specificity, and AUC of miR-155 were 88.9%, 96.7%, and 0.934; respectively (p < 0.001). While those of miR-195 were 73.3%, 60%, and 0.716; respectively (p = 0.001). MIC-B expression showed a 77.8% sensitivity, 80% specificity, and 0.811 AUC at a cutoff of 1.17 ng/ml (p < 0.001). Combined expression of miR-155 and miR-195 achieved a sensitivity of 91.1%, a specificity of 96.7%, and AUC of 0.926 (p < 0.001). Multivariate analysis showed that PDL-1 (OR:13.825, p = 0.004), CTLA-4 (OR: 20.958, p = 0.010), PD-1(OR:10.550, p = 0.044), MIC-B (OR: 17.89, p = 0.003), miR-155 (OR: 211.356, P < 0.001), and miR-195(OR:0.006, P < 0.001) were considered as independent risk factors for BC. Conclusions The PB levels of PDL-1, CTLA-4, PD-1, FOXP3, MIC-B, miR-155, and miR-195 could be used as promising diagnostic markers for BC patients.https://doi.org/10.1186/s10020-025-01137-1Breast cancerMIC-BMiR-155MiR-195PDL-1FOXP3 |
| spellingShingle | Eman A. Al-Sharabass Motawa E. EL-Houseini Heba Effat Sherif Abdelaziz Ibrahim Mona S. Abdellateif The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer Molecular Medicine Breast cancer MIC-B MiR-155 MiR-195 PDL-1 FOXP3 |
| title | The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer |
| title_full | The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer |
| title_fullStr | The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer |
| title_full_unstemmed | The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer |
| title_short | The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer |
| title_sort | clinical potential of pdl 1 pathway and some related micro rnas as promising diagnostic markers for breast cancer |
| topic | Breast cancer MIC-B MiR-155 MiR-195 PDL-1 FOXP3 |
| url | https://doi.org/10.1186/s10020-025-01137-1 |
| work_keys_str_mv | AT emanaalsharabass theclinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer AT motawaeelhouseini theclinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer AT hebaeffat theclinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer AT sherifabdelazizibrahim theclinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer AT monasabdellateif theclinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer AT emanaalsharabass clinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer AT motawaeelhouseini clinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer AT hebaeffat clinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer AT sherifabdelazizibrahim clinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer AT monasabdellateif clinicalpotentialofpdl1pathwayandsomerelatedmicrornasaspromisingdiagnosticmarkersforbreastcancer |